With the choice of antifungal chemotherapeutic agents suitable for use in treatment of the mycoses still severely limited, it is essential to examine all potential additions to the clinical armamentarium. Ambruticin (W7783) is a recently described antifungal antibiotic isolated from Polyangium cellulosum var. fulvum (6a, 7) that has such potential.
With the choice of antifungal chemotherapeutic agents suitable for use in treatment of the mycoses still severely limited, it is essential to examine all potential additions to the clinical armamentarium. Ambruticin (W7783) is a recently described antifungal antibiotic isolated from Polyangium cellulosum var. fulvum (6a, 7) that has such potential.
A cyclopropyl pyran, ambruticin already has been shown to have antifungal activity in vitro against a variety of filamentous fungal pathogens (7) and also to be both protective and curative in vivo in mice experimentally infected with Coccidioides immitis (5, 6) . The following study was undertaken to further define the in vitro spectrum of ambruticin and to compare the in vitro antifungal activity of this new compound with the various drugs of choice used in treatment of the several different groups of human mycotic infections ( 
RESULTS
Results obtained with filamentous and dimorphic agents causing the systemic, opportunistic, and subcutaneous mycoses are shown in Table 2 . Data for amphotericin B and miconazole are consistent with previously published results (2, 9, 10). Most isolates of C. immitis, Histoplasma capsulatum, and Blastomyces dermatitidis were susceptible to all three drugs at concentrations of 1.0 rg/ml or less; the geometric mean MICs (G-MIC) ranged from 0.07 to 1.11 ,tg/ml. Ten isolates of C. immitis were highly susceptible to ambruticin; 90% tested were inhibited by 0.5 ,ig/ml (G-MIC = 0.41 Ag/ml); five of seven isolates of H. capsulatum also were inhibited by 0.5 ,tg of ambruticin per ml (G-MIC = 0.50,g/ml). Tolnaftate was by far the most active drug against the majority of the dermatophytic fungi tested ( Table 3 ). The MICs ranged from 0.063 or less to 8 ,ug/ml, and 82% of the isolates tested were inhibited by 1 ,tg or less of the drug per ml.
Microsporum canis was uniquely susceptible to Results obtained from this study clearly showed that ambruticin was much less active than the other agents against most isolates of Candida species and Torulopsis glabrata (Table 4). Among the Candida species, Candida parapsilosis was more susceptible, while Candida tropicalis and Candida albicans were much less so. All nine isolates of T. glabrata were resistant to 128 jig of ambruticin per ml.
DISCUSSION
The results with ambruticin and the systemic fungal pathogens, C. immitis, H. capsulatum, and B. dermatitidis, are most encouraging, as the majority of isolates of these three fungi were susceptible to less than 1 ,tg of this drug per ml.
These in vitro results correlate well with results of in vivo experiments with murine coccidioidomycosis in which Levine and Ringel found a high percentage of biological cures, approximately 70%, in mice infected with otherwise lethal doses of C. immitis and treated orally with ambruticin (5, 6). Similar results have been obtained in mice experimentally infected with H. capsulatum (11) . Infections caused by the dermatophytic fungi are among the most common diseases of humans. This study clearly indicated that ambruticin has in vitro and possibly clinically useful activity against many of the dermatophytic fungi. Although ambruticin was not as active in vitro as tolnaftate, it was comparable to miconazole.
Pharmacological data for this new drug are not yet available. However, peak serum ambruticin levels in mice of 46 ,ug/ml at 1 h following a 75-mg/kg oral dose of ambruticin have been reported (6a,). Thus, the range of clinically significant in vivo susceptibility for this compound may be as high as 8 to 16 ,ug/ml. Approximately 70% or more of the isolates of A. fumigatus, S. schenckii, and the dematiaceous fungi were susceptible to ambruticin at such concentrations. Ambruticin also was inhibitory for four of seven isolates of A. boydii and 13 of 15 isolates of A. fumigatus at similar concentrations. Further pharmacologic studies are needed to validate the assumption that 8 to 16 ,ug/ml represents the upper range of probable in vivo susceptibility to ambruticin.
In this study ambruticin was found to be poorly active or inactive in vitro against monomorphic pathogenic yeasts. In view of the in vivo results reported for ambruticin and dimorphic pathogens, in vivo studies are required to properly evaluate the potential efficacy of this drug in infections caused by yeasts. Further, the observed differences between susceptibilities of yeasts and of filamentous pathogenic fungi to ambruticin, as well as the occurrence of a large number of organisms with apparent primary resistance, suggest an apparently selective mode of action of this new antifungal compound.
